Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598334 | 0.80 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL4597346 | 0.77 | SMN1; SMN2 (0.36) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL4596641 | 0.76 | MAPT (0.34) | MEN1KMT2AMAPTTP53F2 | |
| SCHEMBL4598335 | 0.73 | — | — | |
| SCHEMBL10595472 | 0.71 | ALDH1A1 (0.40) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL19846093 | 0.67 | LMNA (0.44) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL19284172 | 0.66 | MEN1 (0.41) | MEN1KMT2ALMNA | |
| SCHEMBL27370766 | 0.66 | HAO1 (0.37) | KMT2A | |
| SCHEMBL594758 | 0.65 | MCL1 (0.41) | MAPTLMNAL3MBTL1 | |
| SCHEMBL19846087 | 0.64 | HPGD (0.41) | MEN1KMT2AMAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | MEN1 4855/4885KMT2A 4627/4885MAPT 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.